CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Dec. 18, 2020—Beckman Coulter launched the Access SARS-CoV-2 Antigen assay, a high-throughput COVID-19 test available in the U.S., priced at $4 to health care providers, including public and private institutions, governments, and nonprofits.
The assay has proven 93 percent positive percent agreement within seven days post-symptom onset and 100 percent negative percent agreement and has a limit of detection of 33 TCID50/mL. Test results are available in as little as 30 minutes on the company’s immunoassay analyzers, including the DxI 800, which can process 200 samples per hour. Samples are collected with a nasopharyngeal swab at the point of care and can be stored at room temperature for up to 24 hours and refrigerated for 48 hours.
Pages: 1 2